Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm
17 avr. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ:...
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Cardinal Health, CURO Group, Sarepta, and PG&E Corporation and Encourages Investors to Contact the Firm
23 janv. 2020 14h25 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of Cardinal Health, Inc....
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Valaris, Sarepta Therapeutics, Canada Goose, and Meredith Corporation and Encourages Investors to Contact the Firm
15 oct. 2019 20h37 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Valaris Plc (NYSE: VAL),...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm
09 oct. 2019 08h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm
02 oct. 2019 21h07 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
24 sept. 2019 09h45 HE
|
Schall Law
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
17 sept. 2019 10h21 HE
|
Schall Law
LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09 sept. 2019 10h56 HE
|
Schall Law
LOS ANGELES, Sept. 09, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
Scott+Scott, Attorneys at Law, LLP Announces Investigation of Sarepta Therapeutics, Inc.
28 mars 2017 11h41 HE
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta...
Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
04 oct. 2016 07h01 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...